Ascenion’s portfolio company OMEICOS reported positive Phase I data for its lead candidate OMT-28, a small molecule with strong anti-arrhythmic and cardioprotective potential. The study, which enrolled 75 subjects at two centers in Germany, showed an excellent safety profile with no signals in vital signs or relevant laboratory parameters up to the maximum dose tested, which was 60 mg. Moreover, pharmacokinetic data support a once daily oral treatment schedule.
Based on this positive outcome, the company has accelerated its plans to initiate a phase II trial in atrial fibrillation, the most common cardiac arrhythmia in humans. If successful, OMT-28 could provide a new, highly safe and effective treatment modality for millions of patients.
Further information: See OMEICOS’ press release
Learn details on the trial (NCT03078738): ClinicalTrials.gov